Trials / Unknown
UnknownNCT00279227
Role of Epicardial Adipose Tissue in Coronary Artery Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (planned)
- Sponsor
- Hamilton Health Sciences Corporation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
We sight to evaluate whether patients with coronary artery disease (CAD) have more epicardial fat than patients without CAD, which would suggest that epicardial fat may be more than an "innocent bystander" and be actively involved in the disease process. Its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. We also sight to evaluate whether epicardial fat from patients with CAD releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. Thus for e.g., the use of thiazolidinediones (glitazones), statins, ARBs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.
Conditions
Timeline
- Start date
- 2006-01-01
- Completion
- 2006-12-01
- First posted
- 2006-01-19
- Last updated
- 2006-08-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00279227. Inclusion in this directory is not an endorsement.